Literature DB >> 29168882

Fibroblast growth factor 2 regulates activity and gene expression of human post-mitotic excitatory neurons.

Shweta Gupta1, Tanya M-Redmond1, Fan Meng1, Andrew Tidball2, Huda Akil1, Stanley Watson1, Jack M Parent2, Michael Uhler1,3.   

Abstract

Many neuropsychiatric disorders are thought to result from subtle changes in neural circuit formation. We used human embryonic stem cells and induced pluripotent stem cells (hiPSCs) to model mature, post-mitotic excitatory neurons and examine effects of fibroblast growth factor 2 (FGF2). FGF2 gene expression is known to be altered in brain regions of major depressive disorder (MDD) patients and FGF2 has anti-depressive effects in animal models of depression. We generated stable inducible neurons (siNeurons) conditionally expressing human neurogenin-2 (NEUROG2) to generate a homogenous population of post-mitotic excitatory neurons and study the functional as well as the transcriptional effects of FGF2. Upon induction of NEUROG2 with doxycycline, the vast majority of cells are post-mitotic, and the gene expression profile recapitulates that of excitatory neurons within 6 days. Using hES cell lines that inducibly express NEUROG2 as well as GCaMP6f, we were able to characterize spontaneous calcium activity in these neurons and show that calcium transients increase in the presence of FGF2. The FGF2-responsive genes were determined by RNA-Seq. FGF2-regulated genes previously identified in non-neuronal cell types were up-regulated (EGR1, ETV4, SPRY4, and DUSP6) as a result of chronic FGF2 treatment of siNeurons. Novel neuron-specific genes were also identified that may mediate FGF2-dependent increases in synaptic efficacy including NRXN3, SYT2, and GALR1. Since several of these genes have been implicated in MDD previously, these results will provide the basis for more mechanistic studies of the role of FGF2 in MDD.
© 2017 International Society for Neurochemistry.

Entities:  

Keywords:  FGF2; glutamatergic; neurogenin-2; neuronal; stem cells

Mesh:

Substances:

Year:  2017        PMID: 29168882      PMCID: PMC5924590          DOI: 10.1111/jnc.14255

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  60 in total

Review 1.  Fibroblast growth factor signaling regulates growth and morphogenesis at multiple steps during brain development.

Authors:  F M Vaccarino; M L Schwartz; R Raballo; J Rhee; R Lyn-Cook
Journal:  Curr Top Dev Biol       Date:  1999       Impact factor: 4.897

2.  Direct transcriptional induction of Gadd45gamma by Ascl1 during neuronal differentiation.

Authors:  Holly S Huang; Ginger M Kubish; Tanya M Redmond; David L Turner; Robert C Thompson; Geoffrey G Murphy; Michael D Uhler
Journal:  Mol Cell Neurosci       Date:  2010-04-09       Impact factor: 4.314

3.  Galanin receptor 1 gene expression is regulated by cyclic AMP through a CREB-dependent mechanism.

Authors:  V Zachariou; D Georgescu; L Kansal; P Merriam; M R Picciotto
Journal:  J Neurochem       Date:  2001-01       Impact factor: 5.372

4.  Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defined culture conditions.

Authors:  Jeanette Beers; Daniel R Gulbranson; Nicole George; Lauren I Siniscalchi; Jeffrey Jones; James A Thomson; Guokai Chen
Journal:  Nat Protoc       Date:  2012-10-25       Impact factor: 13.491

5.  Kallmann's syndrome: a comparison of the reproductive phenotypes in men carrying KAL1 and FGFR1/KAL2 mutations.

Authors:  Sylvie Salenave; Philippe Chanson; Hélène Bry; Michel Pugeat; Sylvie Cabrol; Jean Claude Carel; Arnaud Murat; Pierre Lecomte; Sylvie Brailly; Jean-Pierre Hardelin; Catherine Dodé; Jacques Young
Journal:  J Clin Endocrinol Metab       Date:  2007-12-26       Impact factor: 5.958

6.  Fibroblast Growth Factor 2 Modulates Hypothalamic Pituitary Axis Activity and Anxiety Behavior Through Glucocorticoid Receptors.

Authors:  Natalina Salmaso; Hanna E Stevens; Jessica McNeill; Maha ElSayed; Qiuyin Ren; Maria E Maragnoli; Michael L Schwartz; Simone Tomasi; Robert M Sapolsky; Ronald Duman; Flora M Vaccarino
Journal:  Biol Psychiatry       Date:  2016-03-02       Impact factor: 13.382

7.  Genome-wide target profiling of piggyBac and Tol2 in HEK 293: pros and cons for gene discovery and gene therapy.

Authors:  Yaa-Jyuhn J Meir; Matthew T Weirauch; Herng-Shing Yang; Pei-Cheng Chung; Robert K Yu; Sareina C-Y Wu
Journal:  BMC Biotechnol       Date:  2011-03-30       Impact factor: 2.563

8.  Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies.

Authors:  S I Shyn; J Shi; J B Kraft; J B Potash; J A Knowles; M M Weissman; H A Garriock; J S Yokoyama; P J McGrath; E J Peters; W A Scheftner; W Coryell; W B Lawson; D Jancic; P V Gejman; A R Sanders; P Holmans; S L Slager; D F Levinson; S P Hamilton
Journal:  Mol Psychiatry       Date:  2009-12-29       Impact factor: 15.992

9.  The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote.

Authors:  Yang Liao; Gordon K Smyth; Wei Shi
Journal:  Nucleic Acids Res       Date:  2013-04-04       Impact factor: 16.971

10.  Novel Function of Sprouty4 as a Regulator of Stemness and Differentiation of Embryonic Stem Cells.

Authors:  Jae-Young Lee; Sunghyun Park; Kwang-Soo Kim; Jeong-Jae Ko; Soohong Lee; Keun Pil Kim; Kyung-Soon Park
Journal:  Dev Reprod       Date:  2016-06
View more
  5 in total

Review 1.  Anti-fibrotic effects of pharmacologic FGF-2: a review of recent literature.

Authors:  David M Dolivo
Journal:  J Mol Med (Berl)       Date:  2022-04-28       Impact factor: 4.599

2.  Regulation of retinal amacrine cell generation by miR-216b and Foxn3.

Authors:  Huanqing Zhang; Pei Zhuang; Ryan M Welchko; Manhong Dai; Fan Meng; David L Turner
Journal:  Development       Date:  2022-01-17       Impact factor: 6.868

Review 3.  Chinese Herbal Medicine in the Treatment of Depression in Parkinson's Disease: From Molecules to Systems.

Authors:  Yi Zhang; Xiaoman Xu
Journal:  Front Pharmacol       Date:  2022-04-13       Impact factor: 5.988

4.  Shortened TDP43 isoforms upregulated by neuronal hyperactivity drive TDP43 pathology in ALS.

Authors:  Kaitlin Weskamp; Elizabeth M Tank; Roberto Miguez; Jonathon P McBride; Nicolás B Gómez; Matthew White; Ziqiang Lin; Carmen Moreno Gonzalez; Andrea Serio; Jemeen Sreedharan; Sami J Barmada
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

5.  Systemic neurotransmitter responses to clinically approved and experimental neuropsychiatric drugs.

Authors:  Hamid R Noori; Lewis H Mervin; Vahid Bokharaie; Özlem Durmus; Lisamon Egenrieder; Stefan Fritze; Britta Gruhlke; Giulia Reinhardt; Hans-Hendrik Schabel; Sabine Staudenmaier; Nikos K Logothetis; Andreas Bender; Rainer Spanagel
Journal:  Nat Commun       Date:  2018-11-08       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.